These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 39120576)

  • 1. HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor.
    Zhang T; Febres-Aldana CA; Liu Z; Dix JM; Cheng R; Dematteo RG; Lui AJW; Khodos I; Gili L; Mattar MS; Lisanti J; Kwong C; Linkov I; Tipping MJ; de Stanchina E; Odintsov I; Ladanyi M; Somwar R
    Clin Cancer Res; 2024 Oct; 30(20):4701-4713. PubMed ID: 39120576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.
    Lee J; Kida K; Koh J; Liu H; Manyam GC; Gi YJ; Rampa DR; Multani AS; Wang J; Jayachandran G; Lee DW; Reuben JM; Sahin A; Huo L; Tripathy D; Im SA; Ueno NT
    J Exp Clin Cancer Res; 2024 Aug; 43(1):236. PubMed ID: 39164784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
    Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
    J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
    Mutlu L; Manavella DD; Bellone S; McNamara B; Harold JA; Mauricio D; Siegel ER; Buza N; Hui P; Hartwich TMP; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner ES; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
    Mol Cancer Ther; 2023 Dec; 22(12):1404-1412. PubMed ID: 37676984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
    von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
    Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
    Pourjamal N; Yazdi N; Halme A; Joncour VL; Laakkonen P; Saharinen P; Joensuu H; Barok M
    Clin Exp Metastasis; 2024 Apr; 41(2):91-102. PubMed ID: 38367127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
    Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
    Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
    ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
    DiPeri TP; Evans KW; Raso MG; Zhao M; Rizvi YQ; Zheng X; Wang B; Kirby BP; Kong K; Kahle M; Yap TA; Dumbrava EE; Ajani JA; Fu S; Keyomarsi K; Meric-Bernstam F
    Clin Cancer Res; 2023 Nov; 29(21):4385-4398. PubMed ID: 37279095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
    English DP; Bellone S; Schwab CL; Bortolomai I; Bonazzoli E; Cocco E; Buza N; Hui P; Lopez S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer Med; 2014 Oct; 3(5):1256-65. PubMed ID: 24890382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins.
    Brown EL; Shmuel S; Mandleywala K; Panikar SS; Berry NK; Rao Y; Zidel A; Lewis JS; Pereira PMR
    J Nucl Med; 2023 Oct; 64(10):1638-1646. PubMed ID: 37385676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling.
    Smith RS; Odintsov I; Liu Z; Lui AJ; Hayashi T; Vojnic M; Suehara Y; Delasos L; Mattar MS; Hmeljak J; Ramirez HA; Shaw M; Bui G; Hartono AB; Gladstone E; Kunte S; Magnan H; Khodos I; De Stanchina E; La Quaglia MP; Yao J; Laé M; Lee SB; Spraggon L; Pratilas CA; Ladanyi M; Somwar R
    Dis Model Mech; 2022 Jan; 15(1):. PubMed ID: 34841430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure.
    Antonarelli G; Corti C; Tarantino P; Salimbeni BT; Zagami P; Marra A; Trapani D; Tolaney S; Cortes J; Curigliano G
    ESMO Open; 2023 Aug; 8(4):101608. PubMed ID: 37467660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
    Hingorani P; Zhang W; Zhang Z; Xu Z; Wang WL; Roth ME; Wang Y; Gill JB; Harrison DJ; Teicher BA; Erickson SW; Gatto G; Kolb EA; Smith MA; Kurmasheva RT; Houghton PJ; Gorlick R
    Mol Cancer Ther; 2022 Aug; 21(8):1318-1325. PubMed ID: 35657346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
    Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor.
    Ogura K; Somwar R; Hmeljak J; Magnan H; Benayed R; Momeni Boroujeni A; Bowman AS; Mattar MS; Khodos I; de Stanchina E; Jungbluth A; Asher M; Odintsov I; Hartono AB; LaQuaglia MP; Slotkin E; Pratilas CA; Lee SB; Spraggon L; Ladanyi M
    Clin Cancer Res; 2021 Feb; 27(4):1184-1194. PubMed ID: 33229458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Transcriptomic Analysis of EWSR1::WT1 Targets Identifies CDK4/6 Inhibitors as an Effective Therapy for Desmoplastic Small Round Cell Tumors.
    Magrath JW; Sampath SS; Flinchum DA; Hartono AB; Goldberg IN; Boehling JR; Savkovic SD; Lee SB
    Cancer Res; 2024 May; 84(9):1426-1442. PubMed ID: 38588409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EWSR1::WT1 Fusions in Neoplasms Other Than Conventional Desmoplastic Small Round Cell Tumor: Three Tumors Occurring Outside the Female Genital Tract.
    Warmke LM; Perret R; Ledoux P; Michot A; Italiano A; Zou YS; Matoso A; Argani P; Ulbright TM; Baumhoer D; Ameline B; Gross JM
    Mod Pathol; 2024 Mar; 37(3):100418. PubMed ID: 38158126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor.
    Slotkin EK; Bowman AS; Levine MF; Dela Cruz F; Coutinho DF; Sanchez GI; Rosales N; Modak S; Tap WD; Gounder MM; Thornton KA; Bouvier N; You D; Gundem G; Gerstle JT; Heaton TE; LaQuaglia MP; Wexler LH; Meyers PA; Kung AL; Papaemmanuil E; Zehir A; Ladanyi M; Shukla N
    Mol Cancer Res; 2021 Jul; 19(7):1146-1155. PubMed ID: 33753552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.